HopeStage
Back to all studies
CompletedNCT04158453

AUT00201: Safety and Effects in Schizophrenia

About this titleRead the official source — NCT04158453
Medication studyAges 18–65United Kingdom
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
LondonSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: October 10, 2019
Recruitment status
Completed
Enrollment listed in the registry
80
Sponsor
Autifony Therapeutics Limited
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United Kingdom
Age range
From 18 Years to 65 Years
Official registry ID
NCT04158453
Official title
Show the full official title

A Randomised, Double-blind, Placebo-controlled, Single and Repeated Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AUT00201 in Healthy Male and Female Volunteers

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

London

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Autifony Therapeutics Limited.

Did this study involve medication?

Yes. The study involved medication, including AUT00201 and Placebo.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies